Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 38Carcinoma, Non-Small-Cell Lung 23Stomach Neoplasms 19Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Esophageal Squamous Cell Carcinoma 17Esophageal Neoplasms 16Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Liver Neoplasms 6Cholangiocarcinoma 6Lung Neoplasms 5Hodgkin Disease 5Biliary Tract Neoplasms 5Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Urinary Bladder Neoplasms 2

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × camrelizumab × Clear all
NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Unknown
68 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡